Related Experiment Videos
Summary
Newer antidepressants like trazodone show fewer side effects than older drugs. However, amoxapine, maprotiline, bupropion, and nomifensine have serious risks, including hypersensitivity reactions and seizures.
Area of Science:
- Pharmacology
- Clinical Toxicology
- Psychopharmiatry
Background:
- Postmarketing and premarketing adverse drug reaction data for several antidepressants are reviewed.
- The safety profiles of amoxapine, maprotiline hydrochloride, trazodone hydrochloride, bupropion hydrochloride, and nomifensine maleate are examined.
Purpose of the Study:
- To discuss the role of new antidepressant agents in managing depressive illness.
- To highlight the adverse effects and toxicities associated with these newer antidepressants.
Main Methods:
- Review of postmarketing adverse drug reaction reports.
- Analysis of premarketing adverse drug reaction data.
- Comparison of safety profiles with standard tricyclic antidepressants.
Main Results:
- Nomifensine was withdrawn due to hypersensitivity reactions (hemolytic anemia).
- Bupropion's US marketing was delayed due to seizures in bulimic patients.
- Amoxapine and maprotiline show higher toxicity in overdose than standard tricyclics, with amoxapine linked to renal failure and increased mortality.
- Maprotiline and bupropion have dose-related seizure risks.
- Trazodone has minimal cardiac effects but can cause hypotension and priapism; overdose toxicity is rare.
Conclusions:
- Trazodone offers advantages over tricyclic and tetracyclic agents regarding side effects and toxicity.
- Clinical trials may not detect rare but serious adverse effects.
- Careful monitoring for adverse drug reactions is crucial for newer antidepressants.